Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

India’s Advinus Signs On With Genzyme In Malaria Research

This article was originally published in PharmAsia News

Executive Summary

Anti-malarial drug research involving Genzyme and others is set to expand with the help of new Indian partner Advinus, just taken on board to develop early-stage candidates

You may also be interested in...



Genzyme CEO Henri A. Termeer On Big Pharma’s Transformation To Becoming Leaner Machines: An Interview With PharmAsia News (Part 2 of 2)

Genzyme CEO Henri A. Termeer, has seen his company grow from a small entrepreneurial venture into one of the world's largest biotech companies. Having held several prestigious positions like deputy chairman of the Federal Reserve Bank of Boston's board of directors and chairman of the board of Medical Simulation Corp, Termeer is recognized globally for his contributions in the field of biotechnology. With a growth record of 20 percent annually for the past five years, Termeer is now looking beyond American shores to keep with the growth momentum. In an interview with PharmAsia News' India bureau during a World Economic Forum meeting in New Delhi, Termeer speaks on the challenges of the global pharmaceutical industry and the role of emerging markets like India and China.

Genzyme CEO Henri A. Termeer On Big Pharma’s Transformation To Becoming Leaner Machines: An Interview With PharmAsia News (Part 2 of 2)

Genzyme CEO Henri A. Termeer, has seen his company grow from a small entrepreneurial venture into one of the world's largest biotech companies. Having held several prestigious positions like deputy chairman of the Federal Reserve Bank of Boston's board of directors and chairman of the board of Medical Simulation Corp, Termeer is recognized globally for his contributions in the field of biotechnology. With a growth record of 20 percent annually for the past five years, Termeer is now looking beyond American shores to keep with the growth momentum. In an interview with PharmAsia News' India bureau during a World Economic Forum meeting in New Delhi, Termeer speaks on the challenges of the global pharmaceutical industry and the role of emerging markets like India and China.

Genzyme Firms Up Long Term, High Investment Plans For India

MUMBAI - U.S. biotech Genzyme has firmed up a long-term, high-investment growth plan for India. The plan includes launch of Genzyme's entire portfolio of 15 drugs over the next three to four years, forging partnerships for research on drugs that are relevant to India, devising access programs and expanding scope of clinical trials on its experimental drugs

Related Content

UsernamePublicRestriction

Register

WI965023

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel